Incorporating a cycloaliphatic epoxide such as cyclohexene oxide into a polyol pre-mix containing an amine catalyst and a halogenated hydroolefin blowing agent such as HCFO-1233zd helps to improve the storage-stability of the pre-mix and to ensure that a thermoset foam prepared therefrom is of satisfactory quality.

The present disclosure relates generally to curable resins, in particular dual-cure resins, and related methods for use in an additive fabrication (e.g., 3-dimensional printing) device.

A vat resin for three-dimensional stereolithography printing of a thiourethane polymer part comprising a liquid mixture including a first type of monomer, a second type of monomer, a photolatent base decomposable upon exposure to a light to form a non-nucleophillic base catalyst having a pKa greater than 7, an anionic step-growth polymerization reaction inhibitor having an acidic group configured to form an acid-base pair with the non-nucleophillic base and a light absorber having an absorbance in the liquid mixture that is greater than an absorbance of the photolatent base at a wavelength of the light used for the exposure. Methods of preparing the vat resin and three-dimensional stereolithography printing a thiourethane polymer part using the vat resin are also disclosed.

The invention provides polyurethane and polyisocyanurate foams and methods for the preparation thereof. More particularly, the invention relates to polyurethane and polyisocyanurate foams having an open-cell, closed-cell or a combination of open and closed cell structure, and methods for their preparation. The foams are produced with a polyol premix composition which comprises a combination of a hydrohaloolefin blowing agent, a polyol and a catalyst which is an adduct of an amine and an organic acid.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I)

##STR00001##

applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

The invention relates to a non-aqueous coating composition comprising a. a polyisocyanate, b. a polyol having an average functionality of more than 3 hydroxyl groups per molecule, c. a metal based curing catalyst for the addition reaction of isocyanate groups and hydroxyl groups, and d. a mercapto carboxylic acid,
wherein the coating composition does not contain a carboxylic acid wherein the carbonyl group of the carboxylic acid is in conjugation with a -electron system.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) ##STR00001##
applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

The invention provides polyurethane and polyisocyanurate foams and methods for the preparation thereof. More particularly, the invention relates to polyurethane and polyisocyanurate foams having an open-cell, closed-cell or a combination of open and closed cell structure, and methods for their preparation. The foams are produced with a polyol premix composition which comprises a combination of a hydrohaloolefin blowing agent, a polyol and a catalyst which is an adduct of an amine and an organic acid.

The present invention relates to a polyol premix composition for rigid polyurethane foams comprising a hydrohaloolefin as foaming agent, an amine catalyst and an aliphatic dicarboxylic acid. The polyol premix composition has a high initial reaction rate when it is reacted with isocyanate and shows smaller deterioration of reactivity over time.

The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I)

##STR00001##

applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.